Ontology highlight
ABSTRACT:
SUBMITTER: Samaniego F
PROVIDER: S-EPMC5278955 | biostudies-literature | 2015 Jun
REPOSITORIES: biostudies-literature
Samaniego Felipe F Hagemeister Fredrick F Romaguera Jorge E JE Fanale Michelle A MA Pro Barbara B McLaughlin Peter P Rodriguez M Alma MA Neelapu Sattva S SS Fayad Luis L Younes Anas A Feng Lei L Berkova Zuzana Z Khashab Tamer T Sehgal Lalit L Vega-Vasquez Francisco F Kwak Larry W LW
British journal of haematology 20150331 6
We conducted a prospective phase II trial of pentostatin, cyclophosphamide and rituximab as initial therapy for patients with previously untreated advanced stage low-grade or indolent B-cell lymphomas (iNHLs). Of 83 evaluable patients, 91·6% attained an overall response and 86·8% a complete or unconfirmed complete response. The 3-year progression-free survival (PFS) and overall survival rates were 73% and 93%, respectively. The 3-year PFS rate was significantly different for different diagnoses ...[more]